Yueju-Ganmaidazao Decoction confers rapid antidepressant-like effects and the involvement of suppression of NMDA/NO/cGMP signaling.

J Ethnopharmacol

Interdisciplinary Institute for Personalized Medicine in Brain Disorders and Research Center for TCM Fang-Zheng, Jinan University, Guangzhou, 510632, China; Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, 226001, China. Electronic address:

Published: March 2020

Ethnopharmacological Relevance: Yueju-Ganmaidazao Decoction (YG) is a multiherbal medicine prescribed for treatment of mood disorder, consisting of two classical traditional Chinese herbal medicine Yueju and Ganmaidazao. Yueju and Ganmaidazao both are used for depression treatment. The combined decoction of Yueju and Ganmaidazao is prescribed to achieve optimal clinical outcomes by dealing with different symptoms of depression. Recent studies indicated ethanol extract of Yueju was capable to confer rapid antidepressant-like response. The antidepressant activity of YG decoction with fast-onset feature remains to be investigated.

Aim Of The Study: Rapid and safe antidepressant treatment is urgently needed. This study aimed to assess the rapid antidepressant-like activity of YG and the underlying mechanism, focusing on NMDA/NO/cGMP signaling.

Materials And Methods: The optimal doses for immediate and persistent antidepressant-like response were first screened using tail suspension test (TST) and forced swimming test (FST) post a single administration of YG. The rapid action was further confirmed by using the chronic mild stress (CMS) and learned helplessness (LH) paradigms. The expressions of NMDA receptor subunits were evaluated post stress and YG. The contributions of NMDA, NO, and cGMP signaling to the antidepressant effect of YG were investigated systematically using pharmacological interventions.

Results: The optimal dose for immediate and persistent antidepressant potential, evidenced with reduced immobility times in TST or FST from 30 min to 7 days, was determined. The rapid antidepressant-like effect was confirmed in CMS and LH paradigms, including instant normalization of sucrose preference behavior. The expression of NMDA subunit NR1 in the hippocampus was reduced from 30 min to 5 days post YG. In animals subjected to CMS and LH, hippocampal NR1 expression increased, reversed by YG. YG's antidepressant-like effect was blunted by pretreatment with the agonists along the signalings including NMDA (75 mg/kg), L-arginine (750 mg/kg) and sildenafil (5 mg/kg) in TST or FST. Conversely, administration of subeffective dose of individual antagonists, including MK-801 (0.05 mg/kg), 7-nitroindazole (30 mg/kg), methylene blue (10 mg/kg), in combination with a subeffective dose of YG, elicited antidepressant effects.

Conclusion: YG conferred rapid antidepressant-like effects, and the antidepressant response was essentially dependent on suppression of NMDA/NO/cGMP signaling.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2019.112380DOI Listing

Publication Analysis

Top Keywords

rapid antidepressant-like
20
yueju ganmaidazao
12
yueju-ganmaidazao decoction
8
antidepressant-like effects
8
suppression nmda/no/cgmp
8
nmda/no/cgmp signaling
8
antidepressant-like response
8
tst fst
8
30 min days
8
subeffective dose
8

Similar Publications

General Anesthesia Occludes Ketamine's Antidepressant Response in a Rodent Model of Chronic Stress.

Psychedelic Med (New Rochelle)

December 2024

Departments of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Introduction: Psychedelic-induced experiences are thought to play an important role in the therapeutic actions of rapid-acting antidepressants. General anesthesia is one scenario in which patients can be rendered unconscious and masked to the psychedelic treatment, providing a simple yet effective method to examine drug-induced changes in the brain devoid of experiences.

Methods: Chronically stressed adult C57/BL6 male mice were given subhypnotic ketamine alone or ketamine and GABAergic anesthetic isoflurane at sedative (0.

View Article and Find Full Text PDF

Ketamine displays efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model. It rapidly reverses anhedonia (CMS-induced sucrose consumption deficit) and attenuates working memory deficit (novel object recognition: NOR) following both systemic (intraperitoneal, i.p.

View Article and Find Full Text PDF

A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.

Int J Neuropsychopharmacol

December 2024

Department of Pharmacology, Pharmacy College, Nantong University, Nantong 226001, Jiangsu, China.

Background: Depression is a prevalent and disabling disorder that poses serious problems in mental health care, and rapid antidepressants are novel treatments for this disorder. Cannabidiol (CBD), a non-intoxicating phytocannabinoid, is thought to have therapeutic potential due to its important neurological and anti-inflammatory properties. Despite major advances in pharmacotherapy in experimental animals, the exact mechanism of antidepressant-like effects remains to be elucidated.

View Article and Find Full Text PDF
Article Synopsis
  • - The delta opioid receptor (DOP) is identified as a potential target for new antidepressants, as its selective agonist KNT-127 shows promise for rapid antidepressant effects while minimizing side effects.
  • - In experiments, KNT-127 reduced behaviors indicative of depression, such as immobility in the forced swimming test and social avoidance in stressed mice, effects that were reversed by inhibitors of mTOR and PI3K pathways.
  • - The study suggests that DOP agonists work by enhancing excitatory activity in the medial prefrontal cortex through the PI3K-Akt-mTOR signaling pathway, particularly by reducing GABA release from specific interneurons.
View Article and Find Full Text PDF

Rationale: Due to the numerous limitations of ketamine as a rapid-acting antidepressant drug (RAAD), research is still being conducted to find an effective and safe alternative to this drug. Recent studies indicate that the partial mGlu receptor negative allosteric modulator (NAM), 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP), has therapeutic potential as an antidepressant.

Objectives: The study aimed to investigate the potential rapid antidepressant-like effect of M-5MPEP in a mouse model of depression and to determine the mechanism of this action.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!